174
AN oral antiviral against Covid for symptomatic adults who are not hospitalized and who do not risk progression to severe forms of the disease. Pfizer announces the launch of a phase 2-3 clinical trial that will evaluate the safety and efficacy of an investigational antiviral drug (PF-07321332) designed to fight the virus. A therapy that could therefore be administered at the first signs of infection.
.